Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ADA meeting

- PMLiVE

Sanofi and Sobi’s haemophilia A treatment shows effective bleed protection in children

Current factor VIII therapies usually require patients to receive treatment multiple times a week

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

Sanofi’s frexalimab shows promise in relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

- PMLiVE

New report reveals ‘major’ financial burdens faced by atopic dermatitis patients

The report, commissioned by Sanofi, analyses the economic impact of the condition

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

- PMLiVE

Positive results for Sanofi’s haemophilia therapy published in The Lancet

Fitusiran reduced annualised bleeding rates by 90% compared to control arms

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Dupixent is now the first and only targeted medicine in the EU for this patient population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links